Large gap with delayed quotes
|
Last quote
06/17/2026
-
23:20:00
|
Bid
06/17/2026 -
21:59:57
|
Bid Volume |
Ask
06/17/2026 -
21:59:57
|
Ask Volume |
|---|---|---|---|---|
|
55.02
-0.10
(
-0.18% )
|
55.00
|
300 |
55.04
|
200 |
Analysis date: 16.06.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 16.09.2025.
Interest
Very strong
Very strong
Four stars since 05.06.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 22.05.2026 at a price of 54.09.
Evaluation
Neutral
Neutral
Based on its growth potential and our own criteria, we believe the share price is currently fairly priced.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded above its moving average since 29.05.2026.
4wk Rel Perf
5.00%
5.00%
The four-week dividend-adjusted overperformance versus SP500 is 5.00%.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 16.09.2025.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.10%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.01%.
Mkt Cap in $bn
10.76
10.76
With a market capitalization >$8bn, BIOMARIN PHARMA is considered a large-cap stock.
G/PE Ratio
2.10
2.10
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
6.06
6.06
The estimated PE is for the year 2028.
LT Growth
12.73%
12.73%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
14
14
Over the last seven weeks, an average of 14 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
35
35
For 1% of index variation, the stock varies on average by 0.35%.
Correlation
0.13
0.13
Stock movements are totally independent of index variations.
Value at Risk
9.70
9.70
The value at risk is estimated at USD 9.70. The risk is therefore 17.60%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
21.05.2003
21.05.2003